MAXCYTE, INC.

Share Issue/Capital Change • Mar 3, 2021

National Storage Mechanism | Additional information

RNS Number : 9363Q

MaxCyte, Inc.

03 March 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

Gaithersburg, Maryland - 3 March 2021: MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission facility, details of which were announced on 2 May 2017, it has recently issued 3,300 shares of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

The new Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company, as at 28 February 2021, following the recent issue of the new Common Stock, is 84,559,246 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 74,329,157; the number of restricted shares of Common Stock trading under the symbol 'MXCL' is 9,900,089 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.  

For further information, please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Accounting Officer	+1 301 944 1660
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith	+44 (0)20 7260 1000
Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams	+44 (0) 20 7710 7600

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering platform technologies that drives the next‐generation of cell and gene-editing therapies. The Company's technology, which is designed to make a meaningful difference for patients, is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 140 cell therapy programs, with more than 100 licensed for clinical use, and the Company has now entered into 12 clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US.

For more information, visit www.maxcyte.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRDKBBNKBKBCNK